Calliditas Therapeutics AB
STO:CALTX

Watchlist Manager
Calliditas Therapeutics AB Logo
Calliditas Therapeutics AB
STO:CALTX
Watchlist
Price: 208 SEK 0.87%
Market Cap: 12.5B SEK
Have any thoughts about
Calliditas Therapeutics AB?
Write Note

Income Statement

Earnings Waterfall
Calliditas Therapeutics AB

Revenue
1.6B SEK
Cost of Revenue
-104.7m SEK
Gross Profit
1.5B SEK
Operating Expenses
-1.8B SEK
Operating Income
-353.1m SEK
Other Expenses
-127.2m SEK
Net Income
-480.4m SEK

Income Statement
Calliditas Therapeutics AB

Rotate your device to view
Income Statement
Currency: SEK
Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023 Mar-2024 Jun-2024
Revenue
Revenue
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
138
N/A
138
N/A
185
+34%
185
+0%
47
-75%
47
N/A
1
-98%
0
-54%
0
N/A
199
+49 542%
229
+16%
279
+22%
343
+23%
405
+18%
803
+98%
944
+18%
1 150
+22%
1 184
+3%
1 207
+2%
1 311
+9%
1 601
+22%
Gross Profit
Cost of Revenue
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(1)
(3)
(7)
(15)
(24)
(35)
(46)
(60)
(65)
(105)
Gross Profit
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
0
N/A
198
N/A
0
N/A
247
N/A
309
+25%
367
+19%
788
+115%
921
+17%
1 114
+21%
1 138
+2%
1 146
+1%
1 246
+9%
1 497
+20%
Operating Income
Operating Expenses
(85)
(112)
(115)
(128)
(132)
(137)
(172)
(193)
(213)
(243)
(257)
(309)
(383)
(459)
(551)
(637)
(754)
(861)
(973)
(1 074)
(1 202)
(1 315)
(1 373)
(1 521)
(1 537)
(1 642)
(1 850)
Selling, General & Administrative
(33)
(36)
(39)
(36)
(34)
(36)
(47)
(50)
(63)
(71)
(71)
(102)
(142)
(182)
(248)
(302)
(390)
(474)
(562)
(653)
(763)
(872)
(968)
(1 040)
(1 047)
(1 163)
(1 314)
Research & Development
(52)
(76)
(76)
(93)
(99)
(99)
(120)
(142)
(150)
(173)
(190)
(209)
(241)
(203)
(230)
(257)
(357)
(381)
(402)
(413)
(413)
(428)
(421)
(498)
(500)
(526)
(558)
Depreciation & Amortization
(0)
0
0
0
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(13)
0
0
0
(17)
0
0
Other Operating Expenses
0
0
1
1
1
(2)
(5)
(1)
0
1
5
2
0
(73)
(73)
(77)
(6)
(6)
(9)
(8)
(13)
(14)
16
18
26
47
22
Operating Income
(85)
N/A
(112)
-32%
(115)
-2%
(128)
-12%
(132)
-3%
(137)
-3%
(33)
+76%
(55)
-64%
(28)
+49%
(58)
-107%
(210)
-264%
(262)
-25%
(382)
-46%
(458)
-20%
(551)
-20%
(438)
+20%
(525)
-20%
(582)
-11%
(632)
-9%
(677)
-7%
(415)
+39%
(394)
+5%
(259)
+34%
(382)
-48%
(391)
-2%
(397)
-2%
(353)
+11%
Pre-Tax Income
Interest Income Expense
(2)
(2)
(1)
(0)
0
1
(2)
1
(2)
4
12
(24)
(51)
(50)
(62)
(30)
13
(7)
17
39
10
(12)
(26)
(50)
(26)
(100)
(115)
Non-Reccuring Items
0
0
0
0
0
0
0
0
(0)
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
(34)
0
0
Total Other Income
0
(0)
(1)
0
0
0
0
0
(3)
0
0
0
(3)
0
0
(0)
(2)
0
0
0
(5)
(0)
0
0
(6)
0
0
Pre-Tax Income
(87)
N/A
(113)
-30%
(115)
-2%
(128)
-11%
(132)
-3%
(136)
-3%
(35)
+74%
(54)
-54%
(33)
+40%
(54)
-65%
(198)
-269%
(286)
-44%
(436)
-53%
(509)
-17%
(613)
-20%
(468)
+24%
(513)
-10%
(589)
-15%
(616)
-5%
(638)
-4%
(409)
+36%
(406)
+1%
(285)
+30%
(433)
-52%
(457)
-6%
(496)
-9%
(468)
+6%
Net Income
Tax Provision
0
0
0
0
0
0
0
0
(0)
(0)
(0)
(0)
(0)
3
4
4
4
(2)
(4)
3
(3)
13
(8)
(19)
(9)
(28)
(12)
Income from Continuing Operations
(87)
(113)
(115)
(128)
(132)
(136)
(35)
(54)
(33)
(54)
(198)
(286)
(437)
(506)
(609)
(464)
(510)
(591)
(619)
(635)
(412)
(393)
(292)
(451)
(466)
(525)
(480)
Income to Minority Interest
0
0
0
0
0
0
0
0
0
0
0
0
3
5
8
13
9
8
5
0
0
0
0
0
0
0
0
Net Income (Common)
(87)
N/A
(113)
-30%
(115)
-2%
(128)
-11%
(132)
-3%
(136)
-3%
(35)
+74%
(54)
-54%
(33)
+39%
(54)
-65%
(198)
-269%
(286)
-44%
(433)
-52%
(501)
-15%
(600)
-20%
(452)
+25%
(500)
-11%
(583)
-17%
(615)
-5%
(634)
-3%
(412)
+35%
(393)
+5%
(292)
+26%
(451)
-54%
(466)
-3%
(525)
-13%
(480)
+8%
EPS (Diluted)
-2.61
N/A
-3.4
-30%
-6.82
-101%
-3.71
+46%
-5.09
-37%
-3.87
+24%
-0.98
+75%
-1.39
-42%
-0.88
+37%
-1.38
-57%
-4.84
-251%
-5.75
-19%
-9.66
-68%
-10.02
-4%
-12.02
-20%
-8.75
+27%
-9.84
-12%
-11.13
-13%
-11.55
-4%
-11.91
-3%
-7.78
+35%
-7.31
+6%
-5.45
+25%
-8.41
-54%
-8.69
-3%
-9.78
-13%
-8.95
+8%

See Also

Discover More